Cargando…
Atezolizumab plus Bevacizumab Followed by Curative Conversion (ABC Conversion) in Patients with Unresectable, TACE-Unsuitable Intermediate-Stage Hepatocellular Carcinoma
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
S. Karger AG
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9485978/ https://www.ncbi.nlm.nih.gov/pubmed/36158590 http://dx.doi.org/10.1159/000526163 |
| _version_ | 1784792177075814400 |
|---|---|
| author | Kudo, Masatoshi |
| author_facet | Kudo, Masatoshi |
| author_sort | Kudo, Masatoshi |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9485978 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | S. Karger AG |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94859782022-09-23 Atezolizumab plus Bevacizumab Followed by Curative Conversion (ABC Conversion) in Patients with Unresectable, TACE-Unsuitable Intermediate-Stage Hepatocellular Carcinoma Kudo, Masatoshi Liver Cancer Editorial S. Karger AG 2022-07-27 /pmc/articles/PMC9485978/ /pubmed/36158590 http://dx.doi.org/10.1159/000526163 Text en Copyright © 2022 by The Author(s) Published by S. Karger AG, Basel https://creativecommons.org/licenses/by-nc/4.0/This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. |
| spellingShingle | Editorial Kudo, Masatoshi Atezolizumab plus Bevacizumab Followed by Curative Conversion (ABC Conversion) in Patients with Unresectable, TACE-Unsuitable Intermediate-Stage Hepatocellular Carcinoma |
| title | Atezolizumab plus Bevacizumab Followed by Curative Conversion (ABC Conversion) in Patients with Unresectable, TACE-Unsuitable Intermediate-Stage Hepatocellular Carcinoma |
| title_full | Atezolizumab plus Bevacizumab Followed by Curative Conversion (ABC Conversion) in Patients with Unresectable, TACE-Unsuitable Intermediate-Stage Hepatocellular Carcinoma |
| title_fullStr | Atezolizumab plus Bevacizumab Followed by Curative Conversion (ABC Conversion) in Patients with Unresectable, TACE-Unsuitable Intermediate-Stage Hepatocellular Carcinoma |
| title_full_unstemmed | Atezolizumab plus Bevacizumab Followed by Curative Conversion (ABC Conversion) in Patients with Unresectable, TACE-Unsuitable Intermediate-Stage Hepatocellular Carcinoma |
| title_short | Atezolizumab plus Bevacizumab Followed by Curative Conversion (ABC Conversion) in Patients with Unresectable, TACE-Unsuitable Intermediate-Stage Hepatocellular Carcinoma |
| title_sort | atezolizumab plus bevacizumab followed by curative conversion (abc conversion) in patients with unresectable, tace-unsuitable intermediate-stage hepatocellular carcinoma |
| topic | Editorial |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9485978/ https://www.ncbi.nlm.nih.gov/pubmed/36158590 http://dx.doi.org/10.1159/000526163 |
| work_keys_str_mv | AT kudomasatoshi atezolizumabplusbevacizumabfollowedbycurativeconversionabcconversioninpatientswithunresectabletaceunsuitableintermediatestagehepatocellularcarcinoma |